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Background: The frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients varies depending on
histological subtype and population investigated. The six most commonly recurring BRCA1 and BRCA2 mutations
previously identified in a founder French Canadian population were investigated in 439 histologically defined
ovarian, fallopian tube and primary peritoneal cancer cases that were ascertained at one hospital servicing French
Canadians. To further assess the frequency of BRCA1/BRCA2 mutations, a defined subgroup of 116 cases were
investigated for all mutations previously reported in this population.
Methods: A PCR-based assay was used to screen 439 ovarian, fallopian tube or extra-ovarian cancers comprised of
serous, high grade endometrioid and mixed cell adenocarcinomas with serous components for specific BRCA1: C4446T
and 2953delGTAinsC and BRCA2: 8765delAG, G6085T, 3398del5 and E3002K mutations. A multiplex bead-array-based
Luminex assay was used to evaluate 19 specific mutations that have ever been reported in French Canadians,
which included the six mutations assayed by PCR, in 116 cases representing all women ascertained within a
defined 3-year window.
Results: A targeted analysis of six mutations identified 34/439 (7.7%) mutation carriers and at least two mutation
carriers for each mutation screened were found. The BRCA1:C4446T mutation was the most frequently identified
variant (15/34, 44.1%) among mutation-positive cases. The expanded mutation screen that also included 13 additional
variants identified 19/116 (16.4%) mutation carriers, where C4446T was the most common variant (8/19, 42.1%)
identified among mutation-positive carriers in this subgroup. Mutations were identified in women with serous,
endometrioid, mixed cell, and undifferentiated adenocarcinomas. Within this subgroup there were 73 high-grade
(G3) serous ovarian carcinomas, the most common subtype, with mutations identified in 19.2% (n = 14) serous cases.
Conclusions: Our results reaffirm that specific BRCA1 and BRCA2 mutations found previously to recur in French
Canadian breast cancer and breast-ovarian cancer families, also recur in women with ovarian cancer not selected for
family history of cancer. The high frequency of mutation carriers rationalizes genetic testing of ovarian cancer patients
in this demographically defined population.
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Epithelial ovarian cancer is the fifth most frequent cause
of cancer deaths in women in developed countries. The
disease is heterogeneous, where serous, endometrioid,
clear cell and mucinous carcinomas are the most com-
mon histological subtypes, and serous carcinomas, par-
ticularly high grade tumours, account for over 70% of all
cases [1]. The poor overall survival rate at less than 30%
is a reflection of the frequent diagnoses at advanced dis-
ease stage, high recurrence rates and development of re-
sistance to chemotherapy [2,3]. Although there are no
molecular predictors of outcome currently in clinical use
[4], studies of specific cohorts suggest that hereditary
genetic factors influence the outcome of ovarian cancer
patients. Recently it has been observed that carriers of
germline BRCA1 or BRCA2 mutations, which confer
significantly increased risk for the hereditary form of
ovarian cancer, exhibit higher response rates to plat-
inum/paclitaxel chemotherapy (the standard of care for
ovarian cancer), a longer progression-free survival, and
improved overall survival as compared with non-carriers
[5-7]. It has been proposed that defects in homologous
recombination repair pathways affected by “Brca” dys-
function render the tumours sensitive to platinum-based
DNA crosslinking agents and emerging therapies such
as polyADP ribose (PARP) inhibitors [4,8]. Given these
observations it has been recommended that identifying
germline BRCA1/BRCA2 mutation carriers may have
important implications in the management of women
with ovarian cancer as targeted therapies such as PARP
inhibitors are introduced into clinical settings [9].
The likelihood of harbouring a germline BRCA1/
BRCA2 mutation depends on the histological subtype
and/or tumour grade of epithelial ovarian cancers.
Mutations are more frequently observed among women
with high-grade serous or endometrioid subtype carcin-
omas as compared with low-grade serous/endometrioid,
mucinous or clear cell subtype carcinomas [10,11]. Mu-
tation carriers with undifferentiated adenocarcinomas of
the ovary, as well as fallopian tube and primary periton-
eal carcinomas, have also been identified [12-14]. Over-
all, BRCA1 and BRCA2 mutation carrier frequencies of
13-15% have been reported for ovarian cancer patients
from the general population [11,12,15-17]. The high in-
cidence of germline BRCA1 and BRCA2 mutations in
ovarian cancer, has suggested that genetic assessment of
women with ovarian cancer especially those with non-
mucinous high-grade serous histology, will improve mu-
tation carrier detection rates [14,18].
In order to assess the feasibility of offering genetic
testing of women with ovarian cancer, it is important to
determine the frequency of BRCA1 and BRCA2 muta-
tion carriers in populations where genetic testing is
available as the prevalence may vary. The large size andcomplex structure of each gene, the vast array of unique
mutations identified, the spectrum of mutations, and the
identification of variants of uncertain clinical signifi-
cance has hampered genetic testing [19]. However, mu-
tation detection has been facilitated by the prevalence of
specific mutations identified in defined populations due
to founder effects [19]. For example, significantly higher
carrier frequencies (one in 40) have been reported for
Ashkenazi Jewish women of Eastern European ancestry
[20,21]. It is also well established that mutation carriers
are significantly enriched in those women with ovarian
cancer who also have a strong family history of breast
and/or ovarian cancer, although a cancer family history
is not a reliable method for identifying women with
BRCA1/BRCA2 mutations [14,22,23].
French Canadian breast cancer and breast-ovarian
cancer syndrome families of the province of Quebec
harbour specific BRCA1 and BRCA2 mutations that
recur in this demographically unique population due to
founder effects attributed to common ancestors [24-32].
We have shown that five specific mutations (BRCA1:
C4446T and 2953delGTAinsC and; BRCA2: 8765delAG,
G6085T, 3398del5) account for the majority (85%) of all
mutation-positive breast cancer and breast-ovarian can-
cer families, where index mutation carriers self-reported
four grandparents of French Canadian descent [27] and
haplotype analysis of these variants showed that they
were likely due to common ancestors [25,26,29,33]. Al-
though there are no official genetic testing guidelines in
the province of Quebec, these research findings have in-
formed genetic testing strategies (to reduce cost) in her-
editary cancer clinics in Montreal, Quebec. Mutation
testing of high risk French Canadians (self-reported
ancestry of at least two or three grandparents), based on
familial breast and ovarian cancer history, involves a
screen for the most common variants and only when
found negative is comprehensive screening performed by
commercial testing by Myriad Genetics. A review of the
BRCA1 and BRCA2 mutation spectrum found in French
Canadian cancer families where comprehensive analysis
was performed supports this strategy [10,24,28]. In
Canada, all genetic testing for BRCA1 and BRCA2 must
be ordered by a cancer genetics professional associated
with a cancer medical genetics clinic, where clinics are
managed by provincial health care jurisdictions.
Although genetic testing for BRCA1 and BRCA2 for
women with ovarian cancer is available in the neighbouring
province of Ontario [34,35], referrals for genetic testing of
ovarian cancer patients is on an ad hoc basis in Quebec.
In a targeted mutation analysis of BRCA1 (C4446T,
2953delGTAinsC, 3768insA) and BRCA2 (2816insA,
8765delAG, G6085T, 6503delTT) mutations found to
recur at least twice in French Canadians, we reported a
mutation carrier frequency of 8% in 99 women with
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type or family history of cancer [36]. Mutation carriers were
found among seven of 74 women with serous (N = 60) and
endometrioid (n = 14) subtype carcinomas and one of
four women with mixed cell subtype cancers, and none
among the mucinous (n = 14) and clear cell (n = 7) subtype
cancers [36]. Carriers harboured the BRCA1:C4446T,
BRCA2:8765delAG and BRCA2:G6085T mutations, with
C4446T being the most common mutation identified.
These findings are in keeping with the carrier frequency of
these variants in French Canadian breast cancer and
breast-ovarian cancer families of the province of Quebec,
Canada [24,27-29]. However, since our report on ovarian
cancer, the spectrum of BRCA1 and BRCA2 mutations in
this population has been further defined through compre-
hensive analyses of both genes, where 19 different patho-
genic mutations in all have been found in French
Canadian cancer families [24,26,27,37]. This includes the
recurring BRCA2:3398del5 mutation found shared by
common ancestors through haplotype analyses (Oros
et al., [26]), and the recurring BRCA2:E3002K mutation,
initially identified as variant of uncertain significance, and
recently reclassified as a pathogenic mutation [37,38].
Thus the existing figure for the BRCA1 and BRCA2 muta-
tion carrier frequency in French Canadian women with
ovarian cancer may be an underestimate.
Due to the small sample size investigated in our initial
study, we have assessed the frequency of the six most fre-
quently reported mutations that were found to recur in
French Canadian cancer families in a larger cohort of 439
(new) cases of histologically defined ovarian cancers that
were from an ovarian cancer bank comprised of speci-
mens collected from the largest French hospital system
servicing gynecologic-oncology patients in Montreal,
Quebec. This includes an evaluation of the newest recur-
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Mixed cell 32 (0)
Undifferentiated 8 (1)




Mixed cell 12 (0)
Undifferentiated 3 (1)
All types 116 (5)
1Mixed cell has components of serous subtype cancer cells; 2fallopian tube adenoca
ovarian carcinoma diagnosed at 91 years of age.the frequency of BRCA1 and BRCA2 mutations, a sub-
group of 116 women with ovarian cancer ascertained
within a three-year window were investigated for muta-
tions using a broader panel of 19 mutations, which in-
cluded the 13 additional variants previously reported in
French Canadian cancer families and thus accounting for
all BRCA1/BRCA2 mutations reported in French
Canadians of Quebec. The findings from this study further
define the spectrum and frequency of germline BRCA1/
BRCA2 mutations in women with ovarian cancer not se-
lected for family history of cancer and could further in-
form the development of mutation-screening policies for
French Canadians in Quebec.
Methods
Study subjects
The study subjects were comprised of 439 women with
epithelial ovarian (n = 429), fallopian tube (n = 7), or pri-
mary peritoneal (extra-ovarian) carcinomas (n = 3) that
were collected as part of the ovarian tumour banking ac-
tivities of the Banque de tissus et données of the Réseau
de recherche sur le cancer of the Fond de recherche du
Québec – Santé (Table 1). The tumour bank contains
tumour tissues ascertained through surgeries that were
collected at one hospital, the Centre hospitalier de
l’Université de Montréal at the Notre Dame Hospital in
Montreal, where at least 88% of cases self-reported
French Canadian ancestry and over 98% consented to
participate in banking activities. Samples from the
tumour bank that were excluded from the study include:
the women least likely to harbour germline BRCA1 or
BRCA2 mutations, such as low-grade endometrioid, mu-
cinous and clear cell carcinomas, or mixed cell cancers
that did not have serous subtype components [10]; sam-
ples where DNA was no longer available for genetic test-
ing; and samples banked prior to 1997 in order to avoidutations
Tumour grade Disease stage3 Mean age of
diagnosis
(range), years
G1 G2 G3 Un-classified I II III IV
12 62 279 16 25 28 275 40 61 (24 – 91)
0 20 9 1 13 2 14 1 58 (41 – 82)
0 11 21 0 6 2 21 3 57 (36 – 77)
12 0 3 4 2 0 6 0 61 (33 – 72)
13 93 312 21 46 32 316 44 61 (24 – 91)
3 11 73 5 7 8 68 9 61 (38 – 82)
0 7 2 0 6 1 2 0 58 (41 – 82)
0 2 10 0 3 1 6 2 60 (40 – 77)
12 0 1 1 1 0 2 0 68 (62 – 71)
4 20 86 6 17 10 78 11 61 (38 – 82)
rcinoma; 3staging information was not available for a women with a serous
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group where BRCA1 and BRCA2 mutation frequencies
had been investigated [36]. Clinical features (also col-
lected as part of banking activities), such as disease
stage, and tumour characteristics such as grade and
histological subtype, were assigned by a gynaecologist-
oncologist and gynecologic-pathologist, respectively, ac-
cording to the criteria established by the International
Federation of Gynecology and Obstetrics, and were pro-
vided by Système d’Archivage des Données en Oncologie
(Table 1). Tumour grade noted as unclassified may have
been a result of pre-operative exposure to chemother-
apy, which has been known to affect histological subtype
classification [39]. Disease stage was not available for
one women with a serous ovarian carcinoma who was
diagnosed at 91 years of age (Table 1).
A personal history of cancer was noted for 51 women of
whom 19 had synchronous cancers reported as follows: 29
were invasive breast cancer (three synchronous); ten
endometrial cancers (all synchronous); four colorectal
cancers (two synchronous); two cases of cervical cancer
(one synchronous with a breast cancer); two lymphomas;
and one case each of kidney cancer (synchronous), lung
cancer (synchronous), multiple myeloma, retroperitoneal
liposarcoma (synchronous) and skin cancer. Informed
consent was obtained from all subjects at banking and, for
this study, was performed in accordance with guidelines
established by the institutional ethical review boards.
To further assess the frequency of BRCA1 and
BRCA2 mutations, a subgroup of 116 women were se-
lected for screening a broader panel of mutations previ-
ously reported in French Canadian cancer families as
described below. Samples were selected from the 439
cases, and included all samples available according to
our inclusion criteria that were ascertained from the
period of 2006 to 2008 (Table 1).
Mutation analysis
Mutation analysis was performed using DNA provided
by the tissue bank that had been extracted from periph-
eral blood lymphocytes (n = 362) or fresh frozen tumour
specimens (n = 77) when peripheral blood DNA was not
available. All of the 439 women were evaluated for BRCA1
(C4446T, 2953delGTAinsC) and BRCA2 (8765delAG,
G6085T, 3398del5, E3002K) mutations found to recur at
least twice in breast and/or ovarian cancer families of
French Canadian descent [24,26,27,29,37]. DNA sam-
ples were screened using established PCR-based screen-
ing assays [26,29] and/or by the Luminex platform as
described below.
The Luminex platform was used to screen the sub-
group of 116 cases (where 111 and five DNA samples
were from peripheral blood lymphocytes or fresh frozen
tumour specimens, respectively) for a broader panel ofBRCA1 (1135insA, 2080insA, 2244insA, 2953delGTAinsC,
3768insA, 3875del4, 5221delTG, C4446T, E352X, G1081A,
Q1846X) and BRCA2 (2816insA, 3034del4, 3398del5,
3773delTT, 6503delTT, 8765delAG, E3002K, G6085T) mu-
tations, which included the six mutations screened in the
whole cohort. Together this panel represented all patho-
genic mutations identified in the French Canadians of
Quebec that were known to us at the time of the study
was conducted, and which included the most frequently
recurring mutations screened by PCR-based assays
[24,27,29,37]. The Luminex platform is a multiplex
bead-array-based technology and was applied according
to the manufacturer’s instructions with the xPONENT®
software package for data management and analyses
(www.luminexcorp.com).
The variants detected by either screening assay were veri-
fied by bidirectional Sanger Sequencing using 3730xl DNA
Analyzer technology (Applied Biosystems) at the McGill
University and Genome Quebec Innovation Centre
(gqinnovationcenter.com). Sequencing chromatograms were
analysed using Chromas© Version 2.3 (Technelysium Pty
Ltd) and compared with BRCA1 (U14680) or BRCA2
(U43746) GenBank reference sequences (www.ncbi.nlm.nih.
gov/). The Human Genome Variation Society (HGVS)
(www.hgvs.org) designation for each mutation is provided
for all mutations investigated in this study. However, for his-
torical reasons, the original mutation nomenclature is re-
ferred to throughout this article.
Results
The selected cases reflect the frequency and distribution
of women with ovarian cancer identified in the general
population
Table 1 describes the characteristics of the 439 women
screened for the most recurrent BRCA1 and BRCA2
mutations identified in the French Canadian population
and the subgroup of 116 cases screened for all of the
mutations identified in the French Canadian population
of Quebec. The subgroup represents all of the cases
that were ascertained within a 2006–2008 window. We
excluded from our analyses, low-grade endometrioid
adenocarcinomas, mucinous cancers and mixed cell
carcinomas lacking serous components, as these are
least likely to harbour germline BRCA1/BRCA2 muta-
tions [10,36]. The distribution of histological subtypes,
tumour grade, disease stage and age at diagnosis within
both groups are within the estimated frequencies ob-
served for epithelial ovarian cancer subtypes found in
the general population [10,36]. This is reflected in the
observation that the majority of women (in the entire
cohort and within the subgroup) are represented by
high grade and late stage serous subtype ovarian
carcinomas, with mean ages of diagnosis approximating
60 years of age.
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in a screen of the most common recurring mutations in
French Canadians
A previous study of French Canadian women with ovar-
ian cancer was limited by both sample size investigated,
and by spectrum of BRCA1 and BRCA2 mutations
screened, where additional mutations have since been
identified and found to recur in this population. [36].
Therefore to assess the contribution of recurring
BRCA1/BRCA2 mutations in ovarian cancer cases from
French Canadians, genomic DNA from 429 ovarian car-
cinomas and 10 fallopian tube or primary peritoneal car-
cinomas was screened for the presence of the two
BRCA1 (C4446T, 2953delGTAinsC) and four BRCA2
(8765delAG, G6085T, 3398del5, E3002K) mutations
using established PCR-based assays (Table 2). These spe-
cific mutations were selected for screening as they re-
flect the most commonly reported mutations found in
French Canadian breast and/or ovarian cancer families
based on the most recent observations from our group
[24,26,27,29,37]. A targeted screening for these six spe-
cific mutations identified 34/439 (7.7%) mutation car-
riers, where at least two mutation carriers for each
mutation screened were identified (Table 2). The
BRCA1:C4446T mutation was the most frequently
found variant (15/34, 44.1%) among mutation-positive
cases. BRCA1 mutation-positive cases were found
among the serous, endometrioid and mixed cell sub-
type adenocarcinomas in contrast to BRCA2 mutation
carriers, which were exclusively found among the ser-
ous subtype tumours.
With one exception, that being a tumour sample har-
bouring a BRCA1:C4446T mutation, all identified
mutations were detected in the germline. There was
trace evidence for the normal allele in the sequencing
chromatogram from the tumour sample containing the
BRCA1 mutation. Although this BRCA1 mutation is
the most commonly reported germline mutation in our
cohort and in the French Canadian population, our
finding does not exclude the possibility that this muta-
tion was somatically derived.Table 2 Frequency of the most common BRCA1 and BRCA2 mu
Histological
subtype






Serous 369 (9) 12 (3.3)* 1 (0.3)
Endometrioid 30 (0) 1 (3.3) 0
Mixed cell 32 (0) 2 (6.3) 1 (3.1)
Undifferentiated 8 (1) 0 0
All types 439 (10) 15 (3.4) 2 (0.5)
*One grade 2 mutation-positive carrier found among each of these mutation-positiGenetic heterogeneity revealed by screening a broader
panel of mutations in a defined subgroup of women with
ovarian cancer
To further investigate the frequency and spectrum of
BRCA1 and BRCA2 mutations in women with ovarian
cancer, the analysis of a larger panel of mutations previ-
ously identified in French Canadian cancer families was
performed using DNA samples from a subgroup of 116
of 439 women (Table 1). We focused our genetic ana-
lyses on this subgroup as it was not financially feasible
to perform this assay on the entire cohort. We also se-
lected this subgroup reasoning that it more accurately
reflected a series. The screening panel was comprised of
11 BRCA1 and eight BRCA2 mutations (Table 3), which
represented all of the BRCA1/BRCA2 mutations known
to occur in French Canadians at the time the study was
conducted, and included the six mutations that were
analysed in the entire cohort of 439 cases (Table 2). All
mutation-positive women who were initially identified
by a targeted screen of six specific mutations using a
PCR-based assay were also identified with the Luminex
platform that was used to screen the subgroup of cases
(data not shown).
As shown in Table 3, this platform identified muta-
tions in 19/116 (16.4%) women, where BRCA1:C4446T
was the most common variant identified among
mutation-positive cases (8/19, 42.1%) and examples of
carriers of all six of the recurring mutations (see Table 2)
were identified with the exception of BRCA2:3398del5
carriers. All mutations were found in the germline. The
19 mutation-positive carriers harboured one of nine dif-
ferent mutations identified from a total of 19 mutations
screened by the Luminex platform (Table 3). Thus using
the expanded screening panel 5/19 (26.3%) additional
mutation-positive carriers were identified in this sub-
group of 116 women, which included two carriers of the
BRCA1:2244insA mutation. Examples of BRCA1 muta-
tion carriers were found among women with serous,
endometrioid and mixed cell subtype cancers in contrast
to BRCA2 mutation carriers, who were found to have
had either serous or undifferentiated adenocarcinomas.tations among French Canadian women with ovarian cancer
BRCA2 positive (%) BRCA1 and
BRCA2
positive (%)
Total 8765delAG G6085T 3398del5 E3002K Total
13 (3.5) 4 (1.1) 5 (1.4)* 3 (0.8)* 5 (1.4)* 17 (4.6) 30 (8.1)
1 (3.3) 0 0 0 0 0 1 (3.3)
3 (9.4) 0 0 0 0 0 3 (9.4)
0 0 0 0 0 0 0
17 (3.9) 4 (0.9) 5 (1.1) 3 (0.7) 5 (1.1) 17 (3.9) 34 (7.7)
ve carriers.


















G1081A c.962G > A 1 (1.1) 0 0 0 1 (0.9)
1135insA c.1016dupA 0 0 0 0 0
E352X c.1054G > T 0 1 (11.1) 0 0 1 (0.9)
2080insA c.1961dupA 0 0 0 0 0
2244insA c.2125_2126insA 1 (1.1) 0 1 (8.3) 0 2 (1.7)
2953delGTAinsCb c.2834_2836delGTAinsC 0 0 1 (8.3) 0 1 (0.9)
3768insAb c.3649_3650insA 0 0 0 0 0
3875del4 c.3756_3759delGTCT 0 0 0 0 0
C4446Tb c.4327C > T 8 (8.7) 0 0 0 8 (6.9)
5221delTG c.5102_5103delTG 0 0 0 0 0
Q1846X c.5536C > T 0 0 0 0 0
All BRCA1 variants 10 (10.9) 1 (11.1) 2 (16.7) 0 13 (11.2)
BRCA2
2816insAb c.2588dupA 0 0 0 0 0
3034del4 c.2806_2809delAAAC 0 0 0 0 0
3398del5 c.3170_3174delAGAAA 0 0 0 0 0
3773delTT c.3545_3546delTT 0 0 0 1 (33.3) 1 (0.9)
G6085Tb c.5857G > T 1 (1.1) 0 0 0 1 (0.9)
6503delTTb c.6275_6276delTT 0 0 0 0 0
8765delAGb c.8537_8538delAG 2 (2.2) 0 0 0 2 (1.7)
E3002K c.9004G > A 2c (2.2) 0 0 0 2 (1.7)
All BRCA2 variants 5 (5.4) 0 0 1 (33.3) 6 (5.2)
All BRCA1 and BRCA2 variants 15 (16.3) 1 (11.1) 2 (16.7) 1 (33.3) 19 (16.4)
aThe six mutations screened in the entire cohort of 439 women with cancer are bolded; bMutations screened in a previous assay of French Canadian women with
ovarian cancer (Tonin et al., [36]). cOne mutation-positive carrier had a grade 2 carcinoma.
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mutation carriers
In this study, we identified a total of 39 mutation-
positive carriers using either a PCR-based assay muta-
tion screen for six specific mutations or multiplex screen
of 19 mutations (Additional file 1: Table S1). For
descriptive purposes, Table 4 summarizes disease stage
and ages of diagnoses according to mutation status
grouped by histotype. BRCA1 mutation-positive car-
riers were identified among all subtypes except for
undifferentiated adenocarcinomas, whereas BRCA2
mutation-positive cases were identified among the ser-
ous and undifferentiated adenocarcinoma subtype can-
cers. Although the study was limited by screening for
founder mutations only, there were no significant dif-
ferences in distribution of BRCA1 and BRCA2
mutation-positive carriers based on comparisons of
histological subtypes, tumour grade, and stage of dis-
ease (data not shown). Although mean age of cancer
diagnosis of BRCA1 mutation carriers (53.8 years,
range 36 – 76 years) was lower than BRCA2 mutationcarriers (58.5 years, range 48 – 74 years) and women
without mutations (61.3 years, range 24 – 91 years),
this difference in age at diagnosis was not statistically
significant, although this statistical analysis may have
been limited by the small sample sizes for each com-
parison group.
There were 51 women that had a personal history of can-
cer that occurred prior to or occurred synchronously with
an ovarian cancer diagnosis, with breast cancer (n = 29
cases) being the most common cancer reported (see
Methods: study subjects section). Nine mutation car-
riers were identified in this group. One of these women
with a prior history of cervical cancer diagnosed at 41
years of age was found to carry a BRCA1:C4446T mu-
tation (Additional file 1: Table S1). The remaining
eight mutation positive carriers were found among the
women who had a prior diagnosis of breast cancer.
Four of these women had breast cancer before age 51
years (Additional file 1: Table S1). Mutation carriers
were found significantly among 27.6% (8/29) cases
with a personal history of both breast and ovarian
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Age of diagnosis,
years (%)

















BRCA1 Serous 15 9 6 0 1 14 0 3 12
Endometrioid 2 2 0 0 0 2 0 0 2
Mixed cell 4 3 1 0 0 4 0 0 4
Undifferentiated 0 0 0 0 0 0 0 0 0
All types 21 14 7 0 1 20 0 3 18
BRCA2 Serous 17 12 5 0 3 13 1 1 16
Endometrioid 0 0 0 0 0 0 0 0 0
Mixed cell 0 0 0 0 0 0 0 0 0
Undifferentiated 1 0 1 0 0 1 0 0 1
All types 18 12 6 0 3 14 1 1 17
BRCA1 or BRCA2 All types 39 (8.9) 26 (13.3) 13 (5.3) 0 4 (4.3) 34 (10.9) 1 (4.8) 4 (5.1) 35 (9.7)
None 400 (91.1) 170 (86.7) 230 (94.7) 13 (100) 89 (95.7) 278 (89.1) 20 (95.2) 74 (94.9) 325 (90.3)
1Staging information was not available for a women found mutation-negative who had a serous ovarian carcinoma diagnosed at 91 years of age.
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(31/410); p < 0.002).
Discussion
Our study reaffirms that specific BRCA1 and BRCA2
mutations found previously to recur in French Canadian
breast cancer and breast-ovarian cancer families, also
recur in women with ovarian cancer not selected for
family history of cancer. This is especially evident with
the number of BRCA1:C4446T mutation carriers (n = 15)
identified in this study, which has been the most com-
monly reported mutation identified in this population and
this has been attributed to shared ancestry as a conse-
quence of common founders [24,25,27-29,32,33]. This
mutation was also the most common mutation found in
our previous study of 74 women with serous and endome-
trioid ovarian cancers screened for specific BRCA1/
BRCA2 mutations [36].
Our study also highlights the significance of the
BRCA2:E3002K mutation in the French Canadian popu-
lation. We found five E3002K mutation-positive carriers
in the cohort of 439 women with ovarian cancer, which
is similar in frequency to the number of carriers of each
of the other three BRCA2 (8765delAG, G6085T,
3398del5) mutations in the same cohort. Although ini-
tially classified as a variant of uncertain clinical signifi-
cance, both the recurrence of this mutation in breast
and/or ovarian cancer families and results of an
in vitro functional assay suggest that this variant is
pathogenic [24,37,38].
A targeted screen of six specific mutations found to
recur in French Canadian cancer families identified 7.7%
of mutation-carrier cases among 439 women withovarian, fallopian tube and primary peritoneal cancers.
Examples of each mutation type were identified at least
twice among mutation carriers, perhaps reflecting
common founders in this population [25,29]. However, a
high frequency of mutation carriers (16.4%) were identi-
fied in an analysis of a subgroup of 116 of the 439
women with cancer that were ascertained during a
defined period of time using an expanded screen, which
included the six most common mutations and an
additional 13 mutations previously reported in French
Canadian cancer families. The BRCA1:C4446T remains
the most common mutation identified, accounting for
42.1% (8/19) of mutation-positive carriers, although the
expanded screening panel identified an additional 26.3%
(5/19) of mutation-positive carriers. This included the
identification of two BRCA1:2244insA mutation carriers.
This mutation has only been reported in one French
Canadian cancer family in our studies [24,27]. During
the course of this study, we further investigated the fre-
quency of this mutation in the remaining cohort (n = 323)
and found no other mutation-positives cases (data not
shown). The results combined suggest that the population
studied is more heterogeneous than previously suspected,
and are consistent with recent analyses of French Canadian
breast cancer and breast-ovarian cancer families where
more comprehensive mutation methods were used [24].
From the genetic analysis of a subgroup of 116 women
with ovarian cancer, we estimate a combined BRCA1
and BRCA2 mutation carrier frequency of 16.4% for
ovarian, fallopian tube and primary peritoneal cancers
classified as serous, high-grade endometrioid, mixed cell
(containing a serous component) or undifferentiated
adenocarcinomas not selected for family history of
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the largest French hospital servicing gynecologic-
oncology patients in Montreal. When matched only for
the seven variants screened in common with our previ-
ous analysis (see Table 3), a mutation frequency of 10.1%
(n = 12) was identified in the subgroup of 116 women
with ovarian cancer as compared with our previous
studies where 10.3% (n = 8) were identified in 78 histo-
logically matched cases. The similarity in mutation fre-
quencies is consistent with our earlier study suggesting
the groups are similar. With respect to our previous
study, expanding the mutation screen to include 12
other mutations captured an additional 5.9% (n = 7) of
mutation-positive carriers. Within this subgroup there
were 73 high-grade (G3) serous ovarian carcinomas,
which represent the most common subtype of ovarian
cancer, and mutations were identified in 19.2% (n = 14)
cases. As our study was limited by the inability to per-
form a comprehensive screen of both BRCA1 and
BRCA2 due to cost limitations and the use of banked
samples rather than a series, the overall frequency of
mutation carriers in ovarian cancer cases not selected
for cancer family history remains unknown. The ques-
tion thus remains whether BRCA1/BRCA2 mutations
have been missed in the French Canadian population of
Quebec. Notable however, is that our mutation screen of
19 specific mutations included all mutations that had
been identified in French Canadian cancer families at
the time the study was initiated. Indeed, targeted muta-
tion screening analyses currently performed in heredi-
tary cancer clinics of Montreal include either a subset or
all of the 19 variants examined in our study in a targeted
mutation screen of high-risk French Canadians. Thus al-
though comprehensive (commercial) mutation screening
follows a mutation-negative test, no new mutations have
been introduced in targeted mutation screen for this
population in hereditary cancer clinics of Montreal. Not-
able is that although our screen was targeted to 19 spe-
cific variants, our estimated carrier frequency of 16.4%
is similar to the overall BRCA1 and BRCA2 mutation
carrier frequency of 13-15% that has been reported for
women with ovarian cancers not selected for family
history or from demographically defined populations,
where more comprehensive whole gene analyses were
conducted [12,14-16,18].
Our carrier frequency in women with ovarian cancer
is higher than a recently reported carrier frequency of
5.1% among French Canadian women with ductal carcin-
oma in situ or invasive breast cancer cases that were also
ascertained from the same population [40]. However, only
six of the 19 BRCA1 (C4446T, 2953delGTAinsC, and
3875del4) and BRCA2 (8765delAG, 3398del5, and
G6085T) mutations screened in our study were evaluated
in this independent report and thus it remains to bedetermined if the carrier frequency in ovarian cancer pa-
tients would exceed that found in women with breast can-
cer ascertained from the same population if similar
genetic testing strategies are used.
Identifying carriers of BRCA1 and BRCA2 mutations
allows for the targeted prevention of ovarian cancer in
family members of ovarian cancer patients. As ovarian
cancer surveillance has not proven effective, cancer pre-
vention through salpingo-oophorectomy significantly
reduces ovarian, fallopian and breast cancer risk in
mutation carriers [41]. In Quebec, genetic testing is rou-
tinely offered to all women with a family history of
breast cancer and breast-ovarian (epithelial type) cancer,
and a personal history of breast and epithelial ovarian
cancer through referral to hereditary cancer clinics. For
women of French Canadian descent a targeted mutation
analysis is performed based on the BRCA1 and BRCA2
mutations found to recur in this population as this is the
most cost effective strategy for mutation detection given
the high frequency of carriers harbouring founder muta-
tions. Although mutation screening has been advocated
for women with ovarian cancer in other jurisdictions in
Canada, such as the province of Ontario [35], it is not
currently routinely offered in Quebec. During the course
of this investigation the Society for Gynecologic Oncol-
ogy issued a clinical practice statement encouraging the
medical community to offer genetic counselling and
testing to all women with ovarian, fallopian tube and
peritoneal carcinoma (www.sgo.org), but The Society of
Gynecologic Oncology of Canada (www.g-o-c.org) has
yet to propose its own recommendations.
An association with family history of breast and ovar-
ian cancers cannot be commented upon in this study, as
this information was not systematically ascertained with
procurement of cases for tumour banking purposes.
However, the apparent enrichment of BRCA1/BRCA2
mutation carriers among ovarian cancer cases with a
prior or coincident invasive breast cancer would advo-
cate genetic testing of ovarian cancer cases with breast
cancer in the French Canadian population. Our previous
study of ovarian cancer cases ascertained from the same
population revealed that mutation status did not always
correlate with a positive family history of breast and/or
ovarian cancer [36] and this observation has also been
made in independent studies of ovarian cancer [14] and
more recently in French Canadian breast cancer cases
not selected for family history of cancer [40]. Moreover,
our previous findings that BRCA1 and BRCA2 muta-
tions were enriched in serous, endometrioid and mixed
cell histological subtype cancers from either unselected
or familial cases [10,36], collectively would suggest that
carrier detection could be advocated for French Canadian
women who develop these subtypes of ovarian cancer, es-
pecially where cost of genetic testing remains an issue.
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Although our mutation analysis was targeted to identify-
ing specific variants, mutation carriers were identified in
16.4% of cases in a defined subgroup of 116 cases, where
42.1% of mutation carriers harboured the most common
BRCA1:C4446T mutation. Our results advocate for the
expansion of the mutation panel used in clinical genetic
testing for the French Canadian population of Quebec,
possibly through use of a two-tier testing strategy (panel
testing followed by full mutation screening if negative)
as is currently available for French Canadian breast and
ovarian cancer families in hereditary cancer clinics affili-
ated with McGill University and University of Montreal
centres. Although the overall cost could be reduced for a
defined population, population-based genetic testing has
not been advocated due to the overall low frequency of
carriers in the French Canadian population of Quebec
[42]. As a significant number of ovarian cancer patients
harbour germline BRCA1/BRCA2 mutations, a targeted
screen for carriers in this defined population has the po-
tential to improve health management of patients and
reduce ovarian cancer risk for their mutation-carrier
family members.Additional file
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